Abstract
We aimed at securing sufficient concentrations of (10)B in boron neutron capture therapy (BNCT) by developing a new drug delivery system. We have designed and developed a novel lipid analog and succeeded in using it to develop the new boron component liposome. It consisted of three different kinds of amino acid derivatives and two fatty acids, and could react directly with the peptide synthesized first on resin by Fmoc solid-phase synthesis. In this study, lipid analog conjugated with HIV-TAT peptide (domain of human immunodeficiency virus TAT protein) and boronophenylalanine (BPA) was synthesized and successfully incorporated into liposomes.
Publication types
-
Evaluation Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Boron Compounds / chemical synthesis*
-
Boron Compounds / chemistry
-
Boron Compounds / therapeutic use
-
Boron Neutron Capture Therapy / methods*
-
Drug Delivery Systems
-
Humans
-
Isotopes / chemistry
-
Isotopes / therapeutic use
-
Lipopeptides / chemical synthesis
-
Lipopeptides / chemistry
-
Lipopeptides / therapeutic use
-
Liposomes / chemistry*
-
Membrane Potentials
-
Neoplasms / radiotherapy
-
Particle Size
-
Phenylalanine / analogs & derivatives*
-
Phenylalanine / chemical synthesis
-
Phenylalanine / chemistry
-
Phenylalanine / therapeutic use
-
Radiation-Sensitizing Agents / chemical synthesis*
-
Radiation-Sensitizing Agents / chemistry
-
Radiation-Sensitizing Agents / therapeutic use
-
tat Gene Products, Human Immunodeficiency Virus / chemical synthesis*
-
tat Gene Products, Human Immunodeficiency Virus / chemistry
-
tat Gene Products, Human Immunodeficiency Virus / therapeutic use
Substances
-
Boron Compounds
-
Isotopes
-
Lipopeptides
-
Liposomes
-
Radiation-Sensitizing Agents
-
tat Gene Products, Human Immunodeficiency Virus
-
Phenylalanine
-
4-boronophenylalanine